Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ilona Steigerwald

Showing results (1-10 of 22) with videos related to

Pageof 3
Sort By:
Pain Practice : the Official Journal of World Institute of Pain|July 6, 2016
In ResponseRalf Baron, Ilona Steigerwald
The Lancet. Neurology|June 13, 2015
Tapentadol prolonged release in the treatment of neuropathic pain related to diabetic polyneuropathyChristian Elling, Maja Galic, Ilona Steigerwald
Pain and Therapy|August 20, 2014
Driving Ability in Patients with Severe Chronic Low Back or Osteoarthritis Knee Pain on Stable Treatment with Tapentadol Prolonged Release: A Multicenter, Open-label, Phase 3b TrialRainer Sabatowski, Rüdiger Scharnagel, Anne Gyllensvärd, et al.
Advances in Therapy|March 12, 2013
Tapentadol prolonged release versus strong opioids for severe, chronic low back pain: results of an open-label, phase 3b studyRafael Gálvez, Michael Schäfer, Guy Hans, et al.
Current Medical Research and Opinion|June 3, 2009
5% lidocaine medicated plaster versus pregabalin in post-herpetic neuralgia and diabetic polyneuropathy: an open-label, non-inferiority two-stage RCT studyRalf Baron, Victor Mayoral, Göran Leijon, et al.
Current Medical Research and Opinion|June 2, 2009
Efficacy and safety of combination therapy with 5% lidocaine medicated plaster and pregabalin in post-herpetic neuralgia and diabetic polyneuropathyRalf Baron, Victor Mayoral, Göran Leijon, et al.
Pain Practice : the Official Journal of World Institute of Pain|April 23, 2014
Effectiveness and Tolerability of a Moderate Dose of Tapentadol Prolonged Release for Managing Severe, Chronic Low Back Pain with a Neuropathic Component: An Open-label Continuation Arm of a Randomized Phase 3b StudyRalf Baron, Uwe Kern, Matthias Müller, et al.
Journal of Pain Research|July 14, 2012
Effectiveness and safety of tapentadol prolonged release with tapentadol immediate release on-demand for the management of severe, chronic osteoarthritis-related knee pain: results of an open-label, phase 3b studyIlona Steigerwald, Matthias Müller, Jolanta Kujawa, et al.
Clinical Drug Investigation|March 24, 2009
Efficacy and safety of 5% lidocaine (lignocaine) medicated plaster in comparison with pregabalin in patients with postherpetic neuralgia and diabetic polyneuropathy: interim analysis from an open-label, two-stage adaptive, randomized, controlled trialRalf Baron, Victor Mayoral, Göran Leijon, et al.
Clinical Drug Investigation|August 6, 2013
Effectiveness and tolerability of tapentadol prolonged release compared with prior opioid therapy for the management of severe, chronic osteoarthritis painIlona Steigerwald, Michael Schenk, Uwe Lahne, et al.
Pageof 3

Showing results (1-10 of 22) with videos related to

Sort By:
Pageof 3
Pain Practice : the Official Journal of World Institute of Pain|July 6, 2016
In ResponseRalf Baron, Ilona Steigerwald
The Lancet. Neurology|June 13, 2015
Tapentadol prolonged release in the treatment of neuropathic pain related to diabetic polyneuropathyChristian Elling, Maja Galic, Ilona Steigerwald
Pain and Therapy|August 20, 2014
Driving Ability in Patients with Severe Chronic Low Back or Osteoarthritis Knee Pain on Stable Treatment with Tapentadol Prolonged Release: A Multicenter, Open-label, Phase 3b TrialRainer Sabatowski, Rüdiger Scharnagel, Anne Gyllensvärd, et al.
Advances in Therapy|March 12, 2013
Tapentadol prolonged release versus strong opioids for severe, chronic low back pain: results of an open-label, phase 3b studyRafael Gálvez, Michael Schäfer, Guy Hans, et al.
Current Medical Research and Opinion|June 3, 2009
5% lidocaine medicated plaster versus pregabalin in post-herpetic neuralgia and diabetic polyneuropathy: an open-label, non-inferiority two-stage RCT studyRalf Baron, Victor Mayoral, Göran Leijon, et al.
Current Medical Research and Opinion|June 2, 2009
Efficacy and safety of combination therapy with 5% lidocaine medicated plaster and pregabalin in post-herpetic neuralgia and diabetic polyneuropathyRalf Baron, Victor Mayoral, Göran Leijon, et al.
Pain Practice : the Official Journal of World Institute of Pain|April 23, 2014
Effectiveness and Tolerability of a Moderate Dose of Tapentadol Prolonged Release for Managing Severe, Chronic Low Back Pain with a Neuropathic Component: An Open-label Continuation Arm of a Randomized Phase 3b StudyRalf Baron, Uwe Kern, Matthias Müller, et al.
Journal of Pain Research|July 14, 2012
Effectiveness and safety of tapentadol prolonged release with tapentadol immediate release on-demand for the management of severe, chronic osteoarthritis-related knee pain: results of an open-label, phase 3b studyIlona Steigerwald, Matthias Müller, Jolanta Kujawa, et al.
Clinical Drug Investigation|March 24, 2009
Efficacy and safety of 5% lidocaine (lignocaine) medicated plaster in comparison with pregabalin in patients with postherpetic neuralgia and diabetic polyneuropathy: interim analysis from an open-label, two-stage adaptive, randomized, controlled trialRalf Baron, Victor Mayoral, Göran Leijon, et al.
Clinical Drug Investigation|August 6, 2013
Effectiveness and tolerability of tapentadol prolonged release compared with prior opioid therapy for the management of severe, chronic osteoarthritis painIlona Steigerwald, Michael Schenk, Uwe Lahne, et al.
Pageof 3